Goldman Sachs initiates Revolution stock with buy rating on oncology platform
Goldman Sachs initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and $267 price target, citing its oncology platform. The stock has surged 338% in the past year, trading at $190.74. Revolution's lead drug, Rasonque, was recently approved for pancreatic cancer, with trials ongoing for other indications. Analysts have raised price targets and earnings estimates following the approval.
How this was made
The 30-second read
Why it matters
The coverage could attract institutional buying and lift RVMD toward its $267 target.
Market read
New analyst coverage provides a fresh catalyst for RVMD, offering a short‑term trading opportunity.
What to watch
Potential reimbursement challenges and competition from other RAS inhibitors could limit upside.
Background
Goldman Sachs' new coverage follows FDA approval of Revolution's lead drug Rasonque and recent analyst upgrades.
Ticker impact
Goldman Sachs initiated coverage on Revolution Medicines with a Buy rating and a $267 price target.
Potential upside toward the $267 target if the rating is widely followed.
Buy rating and target are new information; market may price in the upside over the next weeks.
Market effects
Boosts confidence in the oncology biotech sector as a new commercial‑stage player gains coverage.
Limited to US biotech investors; no broader regional effect.
Minor global impact; primarily affects US‑listed biotech portfolios.
Counterpoint
The high valuation may be premature given early commercial stage and execution risk.
Key entities
- companyRevolution Medicines Inc.
Oncology biotech developing RAS‑targeted therapies.
- analystGoldman Sachs
Investment bank initiating coverage with a Buy rating.
